Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEAL study of zibotentan + dapagliflozin in cirrhosis with portal hypertension
2023-505405-17-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in Cirrhosis and Portal Hypertension (PH) comparing Zibotentan + dapagliflozin, Dapagliflozin monotherapy and Placebo (3 arms). Primary endpoint: Absolute change in hepatic venous pressure gradient from baseline to Week 6. Started Jul 2023; status: completed.
02
Drugs
zibotentandapagliflozin
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on 2023-505405-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505405-17-00.